AR006202A1 - Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene - Google Patents
Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contieneInfo
- Publication number
- AR006202A1 AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- treatment
- ige
- ige antagonist
- compositions containing
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 210000002966 serum Anatomy 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61422096A | 1996-03-12 | 1996-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006202A1 true AR006202A1 (es) | 1999-08-11 |
Family
ID=24460327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100986A AR006202A1 (es) | 1996-03-12 | 1997-03-12 | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0904108A1 (es) |
| JP (1) | JP2001505181A (es) |
| AR (1) | AR006202A1 (es) |
| AU (1) | AU726143B2 (es) |
| CA (1) | CA2246427A1 (es) |
| IL (1) | IL126113A0 (es) |
| WO (1) | WO1997033616A1 (es) |
| ZA (1) | ZA971607B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| WO2001040264A2 (en) * | 1999-12-06 | 2001-06-07 | Panacea Pharmaceuticals, Llc. | Peptide antigens |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| US6787524B2 (en) | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
| US20040146502A1 (en) * | 2001-05-03 | 2004-07-29 | Elisabeth Latour | Use of organic compounds |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| CN114028569B (zh) * | 2021-12-20 | 2023-04-28 | 中国医学科学院基础医学研究所 | 免疫球蛋白IgE在诊断和/或治疗高血压中的用途 |
| CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US4940715A (en) * | 1988-05-17 | 1990-07-10 | Kissei Pharmaceutical Co., Ltd. | 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities |
| JP3156237B2 (ja) * | 1991-12-24 | 2001-04-16 | 雪印乳業株式会社 | 抗ヒトIgE モノクローナル抗体 |
-
1997
- 1997-02-25 ZA ZA971607A patent/ZA971607B/xx unknown
- 1997-03-06 EP EP97908025A patent/EP0904108A1/en not_active Withdrawn
- 1997-03-06 JP JP53267597A patent/JP2001505181A/ja active Pending
- 1997-03-06 AU AU19875/97A patent/AU726143B2/en not_active Ceased
- 1997-03-06 CA CA002246427A patent/CA2246427A1/en not_active Abandoned
- 1997-03-06 IL IL12611397A patent/IL126113A0/xx unknown
- 1997-03-06 WO PCT/US1997/003443 patent/WO1997033616A1/en not_active Ceased
- 1997-03-12 AR ARP970100986A patent/AR006202A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001505181A (ja) | 2001-04-17 |
| EP0904108A1 (en) | 1999-03-31 |
| ZA971607B (en) | 1998-08-25 |
| WO1997033616A1 (en) | 1997-09-18 |
| AU1987597A (en) | 1997-10-01 |
| AU726143B2 (en) | 2000-11-02 |
| IL126113A0 (en) | 1999-05-09 |
| CA2246427A1 (en) | 1997-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE138562T1 (de) | Transmukosale dosisform | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| KR101900520B1 (ko) | 복합 조성물 | |
| PT88985A (pt) | Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina | |
| ES2171469T3 (es) | Composicion administrada por via nasal y preparacion que la contiene. | |
| EP1064000A4 (en) | VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS | |
| ATE185268T1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| ES2182899T3 (es) | Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii. | |
| ATE94393T1 (de) | Dosisform zur oralen verabreichung des hypoglykaemischen glipizids. | |
| DK0416950T3 (da) | Medikamenter | |
| MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
| AU1935788A (en) | A process for producing an administration and/or dosage form for medically active ingredients of drugs | |
| AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| ES2139842T3 (es) | Uso de la melatonina para tratar a pacientes que sufren drogodependencia. | |
| DK0412554T3 (da) | Sustained-release-præparat til administration i hjernen | |
| ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
| KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
| ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
| JPS6360940A (ja) | 白内障の予防または治療剤 | |
| AR002727A1 (es) | El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion. | |
| ES2038847T3 (es) | Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines. | |
| ES2211594T3 (es) | Medicamentos que contienen acido pantotenico para el tratamiento de enfermedades inflamatorias de las articulaciones. | |
| AR034036A1 (es) | Inhibidor de aromatasa en una dosis unica para tratar la infertilidad | |
| EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique |